Valuation: Incyte Corporation

Market Cap 24.93B 21.65B 20.11B 18.54B 34.93B 2,380B 35.56B 238B 93.21B 1,182B 93.62B 91.57B 3,975B P/E 2026 *
56.6x
P/E 2027 * 17x
Enterprise Value 20.68B 17.96B 16.68B 15.38B 28.98B 1,974B 29.5B 197B 77.32B 981B 77.66B 75.96B 3,298B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 3.07x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day-3.23%
1 week+5.40%
Current month+8.50%
1 month+8.50%
3 months+29.10%
6 months+22.90%
Current year+24.52%
1 week 117.25
Extreme 117.25
132.6
1 month 110.56
Extreme 110.56
132.6
Current year 89.25
Extreme 89.25
132.6
1 year 73.8
Extreme 73.805
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
23/7/26 Free

Chief Technology Officer

15,425 0.0077%
23/7/26 Free

EVP, Head of Incyte Intl

28,921 0.0145%
16/7/26 Free

EVP & Chief Scientific Officer

46,244 0.0231%
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%+5.40%+58.59%+94.94% 24.93B
+6.17%+13.26%+33.13%-1.04% 75.12B
+4.06%-8.25%+18.51%+180.30% 47.63B
+3.25%+52.70%+52.70%+52.70% 49.48B
-3.81%+6.32%-54.61%-54.17% 42.95B
-0.62%+3.64%+64.19%-21.60% 30.72B
+6.29%+1.58%+80.16%-51.19% 22.98B
-1.59%-3.61%-11.53%+150.58% 19.56B
+0.76%+4.15%+76.71%+131.26% 17.19B
-1.68%-0.95%+80.05%+138.64% 16.06B
Average +0.56%+2.90%+39.79%+62.04% 34.66B
Weighted average by Cap. +1.62%+3.86%+32.56%+48.31%

Financials

2026 *2027 *
Net sales 5.94B 5.16B 4.79B 4.42B 8.33B 567B 8.48B 56.75B 22.22B 282B 22.32B 21.83B 948B 6.22B 5.41B 5.02B 4.63B 8.72B 594B 8.88B 59.42B 23.27B 295B 23.37B 22.86B 992B
Net income 452M 393M 365M 336M 633M 43.15B 645M 4.32B 1.69B 21.43B 1.7B 1.66B 72.07B 1.48B 1.29B 1.19B 1.1B 2.08B 141B 2.11B 14.14B 5.54B 70.22B 5.56B 5.44B 236B
Net Debt -4.25B -3.69B -3.43B -3.16B -5.95B -406B -6.06B -40.58B -15.89B -201B -15.96B -15.61B -678B -5.81B -5.05B -4.69B -4.32B -8.14B -555B -8.29B -55.5B -21.73B -276B -21.83B -21.35B -927B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
30/07/26 USD 122.99 -3.23% 2,628,292
29/07/26 USD 127.10 -2.18% 2,917,698
28/07/26 USD 129.93 +9.30% 5,921,515
27/07/26 USD 118.87 +1.02% 2,729,176
24/07/26 USD 117.67 +0.84% 1,207,106
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
122.99USD
Average target price
122.86USD
Spread / Average Target
-0.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock